Élisabeth Angellier

Institut Curie — France

Medicine · Health Sciences

7h-index129citations18works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Palliative Care and End-of-Life Issues(4), Cancer Treatment and Pharmacology(4), Cancer survivorship and care(3), Breast Cancer Treatment Studies(3), Lung Cancer Treatments and Mutations(3)

Publications18 total

From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics
BMC Medical Ethics·2022· 7 citedOpen Access
Refusal of anti-coronavirus disease 2019 vaccination in cancer patients: Is there a difference between the sexes?
European Journal of Cancer·2021· 13 citedOpen Access
Déficience intellectuelle et cancer chez l’enfant : analyse des pratiques concernant le choix du traitement
Bulletin du Cancer·2021· 1 cited
Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre
BMJ Supportive & Palliative Care·2021· 8 citedOpen Access
Palliative care in day-hospital for advanced cancer patients: a study protocol for a multicentre randomized controlled trial
BMC Palliative Care·2021· 10 citedOpen Access
Expérience des soins et de la vie quotidienne pendant le confinement sanitaire national chez des patients suivis et traités en centre de lutte contre le cancer : l’enquête BaroCov
Bulletin du Cancer·2021· 7 citedOpen Access
Les soins palliatifs précoces et intégrés en oncologie
Bulletin du Cancer·2019· 26 citedOpen Access
06 / IS RESPITE CARE A REALITY IN ONCOLOGY?
2018
1118 A cancer can hide another: Survey of a cohort
European Journal of Cancer·2015
Analysis of the impact of growth factor on the haematological safety of dose-dense regimen in the randomized phase II adjuvant trial BO3
Journal of Clinical Oncology·2009
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Annals of Oncology·2006· 40 citedOpen Access
Encéphalopathie aiguë fatale secondaire à un traitement par 5-fluoro-uracile
La Presse Médicale·2005· 1 cited
AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer
Journal of Clinical Oncology·2005· 5 cited
Quel lien établir avec le malade cancéreux, et pourquoi ?
Le Coq-héron·2005
Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study
Journal of Clinical Oncology·2004· 1 cited
Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study
Journal of Clinical Oncology·2004
A new Unstable α2‐Globin Gene Variant: Hb Chartres [α33(B14)Phe→Ser]
Hemoglobin·2003· 9 cited
Acute cutaneous reactions induced by docetaxel: a case report.
PubMed·2002· 1 cited

Frequent Co-authors

Jean François Berdah(5), Carole Bouleuc(4), D. Serin(3), Franck Priou(3), P. Laplaige(3), S. Greget(3), É. Teissier(3), Michel Fabbro(3), Alexis Burnod(3), Pascal Piedbois(2), B. Valenza(2), Marie-Ange Massiani(2), Henri‐Corto Stoeklé(2), Sakina Sekkate(2), Christian Hervé(2), Philippe Beuzeboc(2), Laura Thery(2), Céline Laouisset(2), Timothée Marchal(2), Sylvie Dolbeault(2)